Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients
- Registration Number
- NCT00879411
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Practical experience report (PER) investigating the effect of Micardis® on the average 24h blood pressure of therapy-naive and therapy-experienced patients
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 670
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description arterial hypertension Micardis -
- Primary Outcome Measures
Name Time Method Efficacy (Change of Systolic Blood Pressure) baseline to 8 weeks Change from baseline in 24h systolic blood pressure (BP) at week 8
Efficacy (Change of Diastolic Blood Pressure) baseline to 8 weeks Change from baseline in 24h diastolic blood pressure (BP) at week 8
- Secondary Outcome Measures
Name Time Method Overall Tolerability Scale 8 weeks Safety and tolerability of Micardis® in the treatment of patients with hypertension over 8 weeks, using 10 point Likert scale with worst score=1, best score=10